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Abstract
One of the most significant complications of vascular surgery is thrombosis,
which is the formation of blood clots at the surgical site. Another significant complication
is stenosis - an overgrowth of cells during the healing process, which narrows the same
artery the surgeons were trying to open. These complications often lead to additional
surgeries and carry increased morbidity and mortality for the patients. Numerous
pharmaceutical agents have been tested to prevent these complications, but the results
have been disappointing. The agents either have unacceptable systemic effects, or they
cannot achieve a controlled, timed release in the circulation. Heparin is the most
commonly used anti-coagulant for anastomotic thrombosis prevention, with numerous
studies employing heparin-immobilized or heparin-coated biomaterials for improved
thrombo-resistance.
In this study, the feasibility of heparin-immobilized electrospun nanofibers as
surgical sutures was explored. Using a novel positively charged amphiphilic copolymer as
well as PLGA and PEO, fibers were successfully prepared via electrospinning and twisted
into uniform yarns. The yarns were characterized using FE-SEM and tensile testing.
Fluorescein conjugated heparin was surface immobilized on the yarns through electrostatic
interactions, and released out from the nanofibers. The therapeutic activity of the
immobilized heparin was tested in vitro also. It was shown that the heparin loading
efficiency was greatest in the yarn containing the highest weight percent of the positively
charged PEI polymer and the release kinetics were more gradual and controlled compared
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to control yarns. Further work needs to be done to improve the mechanical properties of
the yarns to make them acceptable for commercial use.
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Chapter 1
Introduction
1.1 Cardiovascular Complications
It is well documented that cardiovascular disease, defined as a class of diseases that
involve the heart or blood vessels, is the leading cause of death in the United States,
responsible for one of every four deaths annually [1]. There are numerous risk factors
that contribute to cardiovascular disease, the most common including: high blood
pressure, diabetes, high cholesterol, tobacco use, poor diet, physical inactivity, obesity,
excessive alcohol consumption, and heredity. While the majority of cardiovascular
problems can be avoided with personal lifestyle changes, surgical intervention is
frequently required to mitigate the likelihood or prevent the occurrence of more serious
conditions such as heart attack, stroke or amputation [2].
With the vast array of vascular procedures performed on a daily basis, the occurrence
of resulting complications vary based on a myriad of variables such as the performance of
the operating surgeon, the patient’s individual biological response to the procedure, preexisting health conditions in the patient prior to surgery, or the actual procedure
performed. Nonetheless, even with all of the variables, two of the most common and
significant complications associated with vascular procedures are thrombosis and stenosis
[3], [4]. Thrombosis is the formation of a blood clot and can lead to vascular occlusion or
emboli formation. Stenosis is the abnormal narrowing of a blood vessel, affecting proper
blood circulation.
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1.2 Free-Tissue Transfer
Moreover, these complications are not limited strictly to cardiovascular disease
procedures. Free tissue transfer, a safe mode of tissue reconstruction, is utilized in a
variety of surgical fields including oral maxillofacial, orthopedic, plastic and
reconstructive, and otolaryngology. It involves the transplantation of tissue from one
location (“donor site”) to the desired location (“recipient site”) and has multiple
indications such as: skeletal defects after debridement for osteomyelitis, breast
reconstruction, and various trunk and extremity defects. Composite tissue
allotransplantation is also a newer form of free tissue transfer used primarily in the face
and hand. For all free flap procedures, blood supply is reconstituted via microsurgical
procedures to connect the vasculature from the native tissue to the graft. Despite
meticulous technique and anti-coagulation drugs, there still exists a significant risk of
thrombosis post-surgery. Thrombotic occlusion is the main cause of graft failure, with
failure occurring in 4 percent of free flaps and up to 30 percent of digital replantations
[5].

1.3 Vascular Anastomosis
In any procedure where vasculature is broken and requires either anastomoses or
ligation, surgical sutures are predominantly used to connect or tie off the vessels. It is at
this location where stenosis and thrombosis occur due to the disruption of the vascular
endothelium, which activates the coagulation cascade and triggers a pro-inflammatory
response [6]. In order to prevent these complications from occurring, it is imperative that
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these mechanisms are limited or prevented entirely. Research has been done that either
indirectly looks to treat the problem or focus on different complications associated with
the application of surgical sutures.

1.4 Surgical Sutures
By definition, a suture is a natural or synthetic strand of textile that is used to
ligate blood vessels and draw tissues together [7]. An ‘ideal’ suture should have adequate
knot/straight strength, with appropriate strength and mass loss for its proposed usage. It
should be pliable and easy to handle, sterile, biocompatible and uniform with predictable
performance [8]. While no suture possesses all of these characteristics, it is left up to the
clinician to select a suture that’s most appropriate for its intended use [9].
Sutures are classified as either absorbable or nonabsorbable, monofilament or
multifilament, and consist of either naturally derived or synthetic materials. They are
available in a wide range of sizes defined by the United States Pharmacopeia (USP).
Absorbable sutures undergo chemical degradation in vivo, most commonly via
hydrolosis. Sutures that lose a significant portion of their tensile strength within 2 months
have been defined as absorbable, but now that current advances in materials have shown
extended tensile retention times for six months or longer, it’s more of a loose definition
[8].
Monofilament sutures are made of a single strand of material, exhibiting lower
tissue drag compared to its multifilament counterpart. Multifilament sutures consist of
multiple strands that are either braided or twisted together, affording greater tensile
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strength, flexibility, and pliability [10]. The capillarity of multifilament sutures, which
can serve as a nidus for bacteria, as well as its increased surface roughness can be
overcome by coating the sutures, simultaneously enhancing the handling characteristics
[8].
Suture manufacturing varies greatly depending on the material. Natural materials
do not require extrusion for fiber formation, while synthetic materials do. Melt extrusion
is the most common form, but gel spinning is sometimes necessary instead. After
extrusion, the fiber is heated and oriented by drawing. This process aligns the molecular
chains in the amorphous region to increase tensile strength along the fiber axis, as well as
reducing fiber diameter. The braiding or twisting of multifilament fibers after orientation
further stretches the fiber to tighten construction and form a single strand. Heat treatment,
including annealing and/or relaxation, is then performed to relieve internal stresses
associated with previous processing and increase dimensional stability. Finally, in some
cases the suture strand is surface coated to impart various desired properties [8].

1.5 Electrospinning
Recently, an electrostatic fiber fabrication technique known as electrospinning has
gained more interest and attention in the biomedical field. Electrospun nanofibers have
high surface area to volume ratio, flexibility in surface functionalities, and mechanical
properties superior to larger fibers [5]. Moreover, the prospect of large scale productions
combined with simplicity in the process makes electrospinning engaging for a variety of
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applications [11]. Specifically, their feasibility as wound dressings, drug delivery, and
molecule immobilization has led to the exploration of their use as surgical sutures.
There are several setup configurations for electrospinning. The typical setup
consists of three main components: a high voltage power supply, a spinneret (e.g. syringe
needle) and a grounded collector. The nanofibers are fabricated by applying a high
electrical charge to a droplet of a polymer solution, causing electrostatic repulsion that
counteracts the surface tension and stretches the droplet. At a critical point a stream of
liquid erupts from the surface forming a ‘Taylor cone’ which is a charged liquid jet that
dries in flight on its way to the grounded collector. As a result of electrostatic repulsion,
the jet is elongated and thinned in flight, forming uniform fibers with nanometer-scale
diameters [12].
The polymer solution is composed of a dissolved polymer in a volatile solvent. A
pump, which holds the syringe containing the polymer solution, regulates the rate at
which the polymer solution is pumped out of the blunt tipped needle. The high voltage
source consists of two electrodes, one from the positive power source, and one connected
to a negative source, acting as the ground. The separation between the needle tip and the
grounded mandrel, known as the gap distance, creates a static electric field [13].
Electrospinning in general is a very complex process due to the multitude of
parameters that directly affect the process itself and the properties of the resulting fibers.
These parameters can be classified into solution parameters, process parameters, and
ambient parameters. Solution parameters include concentration, molecular weight of
polymer, viscosity, surface tension, and conductivity/surface charge density. Processing
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parameters include the applied voltage, feed rate/flow rate, collector type and tip to
collector distance (gap distance). Ambient parameters include humidity, temperature, etc.
[12].

1.6 Thrombosis & Stenosis
In order to address the problems of thrombosis and stenosis, it is important to
fully understand what causes each and their respective mechanisms of action. Thrombosis
is caused by one or more of three factors known as Virchow’s triad: hypercoagulability,
endothelial cell injury, and disturbed blood flow. Injury to the endothelium causes the
exposure of the underlying collagen that causes platelets to bind and activate, triggering
the coagulation cascade and ultimately leading to the formation of a fibrin clot. This is
the chief factor associated with thrombosis caused by surgical intervention. The
disturbance of blood flow is a secondary factor, as the hemodynamics will be affected by
the presence of a suture as well as the resulting endothelial surface morphology of the
anastomosed vessel.
Stenosis, the abnormal narrowing of blood vessels, is most commonly caused by
atherosclerosis and characterized by intimal lesions that protrude into and obstruct
vascular lumens and weaken the underlying media. The contemporary view of its
pathogenesis is a chronic inflammatory response initiated by injury to the endothelium.
The injury results in endothelial activation and dysfunction, yielding increased
permeability and leukocyte adhesion. Monocytes then migrate into the intima where they
transform into macrophages and foam cells. Release factors from activated platelets,

6

macrophages, or vascular cells cause the migration of smooth muscle cells from the
media to the intima. Proliferation of VSMCs is highest in the first week after injury and
can continue for 14–28 days depending on the severity of the injury [14]

1.7 Heparin
By understanding the pathology of thrombosis and stenosis as associated with
vascular procedures, a focused approach can be taken to mitigate these complications. In
the vascular surgery literature, the use of anticoagulation drugs has been shown to
improve surgical outcomes and patency rates. Microvascular literature discusses the use
of three main pharmacologic agents; heparin, aspirin, and dextran, as an adjunct to
preventing thrombosis [4]. Heparin, a well-established anticoagulant, is the most
commonly used agent for anastomotic thrombosis prevention, with numerous studies
employing heparin-immobilized or coated biomaterials for improved thrombo-resistance.
Specifically, immobilized heparin on biomedical devices is known to reduce platelet
adhesion, increase plasma re-calcification time, and increase activated partial
thromboplastin time (APTT) better than soluble heparin [15]. Moreover, it has been
shown to have anti-proliferative effects on smooth muscle cells when administered in
higher doses [16].
Heparin is a glycosaminoglycan containing a mixture of linear polysaccharides
having 2-O-sulfo-α-L-iduronic acid, 2-deoxy-2-sulfamino-6-O-sulfo-α-D-glucose, β-Dglucuronic acid, 2-acetamido-2-deoxy-α-D-glucose, and α-L-iduronic acid as major
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saccharide units joined through 1-4 glycosidic linkages. It’s a relatively large
polysaccharide, with its molecular weight ranging from 5,000-40,000. It has multiple
chemically reactive functional groups, with each disaccharide repeating unit containing a
carboxyl group. All repeating units have one or more 1˚ or 2˚ hydroxyl groups and
approximately 2-2.5 sulfo groups. N-sulfo groups are present in 75-85% of all repeating
units [15].

Scheme 1. General Structure of Heparin; X=H or SO3; Y=Ac or SO3
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Chapter 2
Current Approaches and State of Knowledge
2.1 Systemic Drug Administration
The majority of treatments currently used to combat thrombosis and stenosis
involve the use of drugs delivered systemically. This approach has been generally
disappointing, with the agents producing unacceptable systemic effects or their inability
to achieve a controlled and sustained release in circulation. A study performed in 2006 by
Chung et. al investigating a combinatorial approach of tirofiban, aspirin, and heparin for
the prevention of microsurgical anastomotic thrombosis in a thrombogenic rat model
showed a significant increase in arterial and venous patency and decrease in thrombus
formation. However, these agents were administered intravenously during surgery [4].

2.2 Localized Drug Administration
With the increasing application of electrospun nanofibers as drug delivery
systems, multiple studies have explored the feasibility of incorporating heparin into the
fibers. In 2006, Luong-Van et al. loaded heparin onto the surface of poly(ε-caprolactone)
electrospun mats and achieved a sustained, diffusionally-controlled release of heparin
over 14 days with no pro-inflammatory response in vitro [14]. A very similar study was
done in 2009 by Su et al. that encapsulated heparin into electrospun poly(L-lactide-co- εcaprolactone) fiber mats via co-axial electrospinning and investigated their effect on
VSMC proliferation in vitro over a seven day period [17].
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It wasn’t until around a decade ago that the notion of incorporating drugs within
or onto the surface of sutures began to be investigated. This approach allows for a
localized delivery of therapeutic agents while avoiding excessive systemic levels, thus
improving the therapeutic index. Moreover, since sutures are already used in essentially
all surgical procedures, drug-eluting sutures would reduce the amount of objects needed
in the surgical bed. This could reduce the chances of infection, create more space on the
sterile tool table, and eliminate the need for additional materials or therapeutics to be
applied to the sutured area.
In a study published in 2008, He et al. successfully fabricated two kinds of drugloaded fibers using blend and coaxial electrospinning techniques. The aligned drugloaded fiber bundles were then further processed into fibrous threads by twisting and hotstretching treatments. The drug used was TCH, a broad-spectrum antibiotic, and PLLA
was the polymer used. In vitro drug release studies showed that the coaxially-spun
threads suppressed an initial burst release while providing a sustained release pattern,
while the blend-spun threads produced a large initial burst release. Although the tensile
strength of the fabricated threads were lower than current commercially used sutures, the
authors believe that their study showed a promising method to develop drug loaded
sutures [18].
A few years later, Hu et al. ran a very similar study, where they combined a
braiding technique with the electrospinning process. The drug that was used was
cefotaxime sodium, a broad spectrum third-generation antibiotic. Moreover, the fibers
were coated with chitosan, due to its favorable blood compatibility and hemostasis
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behavior. The polymer of choice (PLLA) for electrospinning was the same as He et al.’s
study as well as their characterization method with the results yielding preferable
morphology and tensile properties as well as favorable antibacterial performance. An in
vivo study was also performed on rats to test for biocompatibility, yielding mild tissue
reactions as compared with two commercial sutures [19].
In 2012, Weldon et al. published a study exploring biodegradable drug-eluting
electrospun sutures for local anesthesia. The sutures were composed of PLGA, an FDA
approved biodegradable polymer used in commercially available sutures, and
bupivacaine hydrochloride, a commonly used amino-amide local anesthetic. The fiber
bundles created were equivalent to 6-0 (~0.08 mm diameter), 4-0 (~0.175 mm), and 2-0
(~0.32 mm) suture gauge sizes. Their results demonstrated similar tissue reaction in vivo
to commercially available sutures as well as adequate mechanical properties for proper
wound healing. The entire drug was released from the suture within 12 days and
maintained approximately 12% of their initial tensile strength after 14 days of incubation
in vitro. The tensile strength of the electrospun sutures was also decreased as the drug
concentration increased, but the strains remained relatively similar from group to group
[20].
In 2013, Lee et al. had a study published in Acta Materialia using a slightly
different approach to drug-loaded sutures. Concerned with the commonly observed
adverse mechanical strength effects of the preparation methods proposed for drugreleasing sutures, their team looked to simply coat commercially used sutures with drugloaded electrospun sheets. PLGA and ibuprofen were electrospun together and then
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braided by hand around the surface of the surgical suture. In vitro release studies and in
vivo animal (rat) pain evaluation studies were conducted as well as the common
mechanical properties tests. Based on their results, they concluded that their suggested
approach is a novel system for postoperative pain relief and that their fabrication method
will allow for numerous different drugs to be used in the future [21].
The most recent study found that also is the most similar to the proposed research
plan in this paper. Dexamethasone (DEX), a glucocorticoid that inhibits inflammatory
processes and proliferation of SMCs, was loaded into PLGA particles using a water-oil
emulsion method. Next, the surface of the particles were treated to enhance their
hydrophilicity and then dispersed in polyethyleneimine (PEI). These PEI-coated particles
were then dispersed in distilled water and a commercially used absorbable suture (4-0
Vicryl) was immersed in the suspension. The positively charged surface of the modified
particles allowed for them to be immobilized onto the suture via electrostatic interactions.
The particles were found to remain on the suture surface after 4 weeks in PBS at 37°C
with a sustained DEX release over the 4-week incubation period. Moreover, the presence
of the immobilized particles did not affect the mechanical properties of the absorbable
sutures [22].
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Chapter 3
Objectives
3.1 Project Rationale & Aims
The goal of this proposed research is to develop a drug-eluting suture
incorporating a novel, cationic, amphiphilic block copolymer, polyethylenimine-g-poly
(D, L-lactide-co-glycolide) (PgP), which we have synthesized in our lab. To create this
suture, we will use electrospinning, a simple and versatile method for developing
polymeric fibers with very small diameters [14], [18], [19], [23], [24].
Once the polymer solution is electrospun into nanofibers, the fibers will be physically
twisted together, forming a uniform yarn. It is hypothesized that heparin, a negatively-charged
anti-thrombotic drug, will bind to the surface of the positively-charged, hydrophilic block of the
PgP polymer (scheme 2). The electrostatic binding between the fiber and heparin molecules will
allow for a sustained release of heparin to aid in the prevention of thrombosis and stenosis. This
localized delivery of heparin to the site of anastomosis will reduce the amount of heparin that
would normally be administered systemically, therefore yielding low systemic effects and
reducing the amount of prophylactic treatments used in typical vascular procedures. Heparin was
selected as therapeutic because of its widely recognized success in biomedical devices as well as
its highly negative charge density that allows it to bind to the positively charged PEI.
Specifically, the aims of this study are as follows:
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Aim 1: Fabricate and characterize the mechanical properties of heparin-loaded
electrospun fibers
Aim 2: Evaluate the loading efficiency and release kinetics of immobilized heparin from
the electrospun yarns
Aim 3: Evaluate the therapeutic activity of released heparin from the electrospun yarn

Scheme 2. Heparin loaded electrospun fiber
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Chapter 4
Materials and Methods
4.1 Materials
Poly (lactic-co-glycolic acid) (PLGA) (50:50, 50 kDa; 50:50, 100kDa) was
purchased from Durect Corporation (Cupertino, CA). Heparin sodium salt from porcine
intestinal mucosa, poly(ethylene oxide) (PEO) (1,000 kDa), anhydrous
dimethylformamide (DMF), N,N-Dimethylacetamide (DMAc), N-hydroxysuccidimide
(NHS), dicyclocarbodiimide (DCC) and branched polyethylenimine (b-PEI) (25kDa)
were obtained from Sigma-Aldrich (St. Louis, MO). Dialysis tubing (MWCO: 50kDa,
300kDa) was obtained from Spectrum labs (Rancho Dominguez, CA). Dimethyl
sulfoxide (DMSO) was obtained from Thermo Fisher Scientific (Waltham, MA).
Disposable PD-10 Desalting Columns were obtained from GE lifesciences (Pittsburg,
PA). 4'-(aminomethyl)fluorescein, hydrochloride was obtained from Molecular Probes
(Eugene, OR).

4.2 Synthesis of polyethylenimine-g-poly (D, L-lactide-co-glycolide) (PgP)
PgP synthesis was carried out using two different molar ratios of PLGA:PEI
(1.2:1 and 10:1 mole ratio). After adding a molecular sieve to DMF overnight to remove
residual water, PLGA (50kDa) was dissolved in the solvent. NHS and DCC was then
added to the reaction solution and stirred at room temperature for 2 hours to activate the
carboxylic acid end group of PLGA. The resulting precipitate, dicyclohexyl urea (DCU)
was filtered using a fine pore size glass funnel. Branched PEI (25kDa) was dissolved in
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dried DMF and added in drop-wise fashion to the activated PLGA filtrate for 30 minutes.
The mixture was allowed to react for 24 hours at room temperature with stirring.
The reaction solution was then pipetted in dialysis membranes (MWCO=50,000)
and dialyzed against deionized water for two days, changing the water at 2, 4, 6, and 24
hour timepoints. The dialyzed product was then centrifuged for 10 minutes at 5,000rpm,
forming a precipitate and supernatant which were separated and lyophilized. After
synthesis and purification, the structure of the PgP was verified by 1H- NMR on a Bruker
300MHz in deuterated DMSO (DMSO-d6).

Scheme 3. Synthesis of PLGA-g-PEI
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4.3 Electrospinning
4.3.1 General Setup
The electrospinning setup used for this study was designed by Dr. Kornev’s group
[25] and consisted of a syringe pump (c) elevated on an adjustable platform, a high
voltage power supply (d), a grounded rotating mandrel collector (e), a charged polymer
solution (b) and a syringe with a blunt tipped needle (a) from which the polymer is
expelled (scheme 3). A heat sleeve was placed around the syringe (not shown) to keep the
polymer heated during the electrospinning process.

Scheme 4. Illustration of ectrospinning apparatus for fabricating and collecting nanofibers

4.3.2. Polymer Solution Formation
PLGA (50:50,100 kDa) was warmed to room temperature (RT) then added to
dimethylacetamide (DMAc) in a glass vial. The solution was capped and stirred with a
stir bar on a stir plate at RT until fully dissolved. PEO (1,000 kDa) was then added and
stirred further with heat (~60˚C) until fully dissolved. Depending on the type of fiber
being spun, PgP was then added and stirred with heat until fully dissolved.
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4.3.3 Electrospinning
Once the polymer was fully dissolved in the solvent, it was added to the syringe
tube, being sure to remove any bubbles between the needle tip and the plunger. The
syringe was then wrapped in the heat sleeve and placed in the syringe pump setup. The
flowrate and inner diameter of the syringe tube was set on the pump, and pumping was
started immediately to ensure the polymer didn’t solidify in the needle. The positive
electrode was clipped to the needle tip and the negative electrode was configured as a
brush that made constant contact with the rotating mandrel. The applied voltage, relative
humidity, gap distance, polymer solution flowrate, mandrel rotation speed and spinning
time were all recorded for each spin. After optimal parameters were determined (through
literature review and trial and error) the controllable parameters were held constant from
batch to batch.
4.3.4 Fiber collection and Yarn Formation
To collect the aligned fibers from the mandrel and twist them into uniform yarns,
a custom made collecting device was used (scheme 4). The brush-like ends were adjusted
to the inner distance between two of the madrel bars. Beginning at the bottom of the
mandrel, the device was slowly raised between the bars while manual spinning the
brushes to collect the fibers, resulting in a cylinder-like web once completed. After fibers
were collected from one of the sides, the collector was placed in its mount, plugged in,
and turned on, causing the brushes to spin in opposite directions and twisting the attached
fibers into a tight, uniform yarn. The twisting time was noted for each batch and held
constant once an optimal time was found for a given fiber. After twisting, the ends of the
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yarn still connected to the brushes was cut with scissors and stored in petri dishes in a
desiccator until further use.

Scheme 5. Custom-made fiber collector and twisting device

4.4 Physical and Mechanical Characterization of Electrospun Yarns
Following fabrication of the yarns, their physical and mechanical properties were
characterized.
4.4.1 Scanning Electron Microscopy
Field Emission Scanning Electron Microscopy (FESEM) was used to observe the
yarns’ surface morphologies as well as the individual fibers’ morphology. Samples were
fixed to a SEM stage using double sided tape and sputter coated with palladium/platinum
for approximately 60 seconds. Using an S-4800 SEM (Hitachi), images were taken at
150x and 1000x magnification with a 12.0kV accelerating voltage applied.
4.4.2 Phase Contrast Microscopy
Phase contrast microscopy (Zeiss Axiovert 200) was used to accurately measure
the diameters of the yarns and observe their uniformity. Three images of each yarn were
taken (from the center portion and the two ends) under 10x magnification. Three
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measurements were then made from each of the three images and the resulting average
diameter was used in calculating the yarns’ tensile properties.
4.4.3 Tensile Testing
In order to characterize the mechanical properties for the various yarns that were
electrospun, a MTS Synergie 100 (MTS Systems Corp.) material testing machine was
used to perform tensile tests on the samples. The machine was connected to a computer
that used the corresponding software (TestWorks® 4) to analyze the data. The yarns were
cut into 5cm segments and clamped into the platents (grips), which were lined with Gator
P100 sandpaper (Ali Industries, Inc.) to prevent slippage. After the given yarn sample
was securely clamped into the platents, the top platent was raised to the point where the
sample was taught but not stressed. The gauge length (distance between platents) was
measured and input into the software, which was maintained as close to 30cm as possible
for consistency. The average diameter of the given sample (measured as described
previously via phase contrast microscopy) was also input into the program prior to
running the test. Using a 100N load cell, the samples were evaluated under uni-axial
tension at a constant rate of 5.0 mm/minute. Tests were run until failure, at which point
the machine was stopped manually.
The software provided load, extension, stress and strain values, as well as peak
load, peak stress, strain at break, and elastic modulus values for each sample. However,
the automated moduli calculations were oftentimes not completely accurate based on
observation of user-created stress-strain plots, so they were manually calculated. This
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was accomplished by selecting two points at random in the linear elastic region of the
plot and finding the slope of imaginary line between them.

4.5 Heparin Immobilization
4.5.1 Fluorescein Conjugation to Heparin
In order to visualize and quantify the amount of heparin that was immobilized to
the electrospun fibers, a fluorophore was covalently bonded to it. Using a method
modified from Osmond et al. [26], a 10% N-(3-dimethylaminopropyl)-N’ethylcarbodiimide hydrochloride (EDC) solution was prepared in 0.1 M 4morpholinoethanesulfonic acid (MES) buffer (pH 4.7). This solution was added to a 1%
heparin solution in MES buffer, activating the carboxylic acid groups of heparin. Next, a
16% 4’-(aminomethyl) fluorescein hydrochloride solution was prepared in
dimethylformamide (DMF) and added to the activated heparin solution, resulting in a
covalent amide bond between the primary amine of the fluorescein and the activated
carboxyl group of the heparin. The reaction mixture was sealed, protected from light and
stirred at room temperature overnight. The fluorescein conjugated heparin (F-heparin)
was purified using disposable PD-10 desalting columns with filtered deionized water and
lyophilized to yield a powdered product.
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Scheme 6. F-heparin conjugation reaction. Adapted from ThermoFisher [27]

4.5.2 F-Heparin Surface Immobilization onto Electrospun Fibers
Pre-weighed electrospun yarns were measured for length, washed 2x in deionized
water and added to individual wells of a 24 well plate. 1 mL of 0.1% F-heparin solution
in PBS (without Ca2+ and Mg2+) was added to half of the samples, while plain PBS was
added to the other half as negative controls. The yarns were protected from light and
incubated at room temperature for 4 hours with gentle shaking. They then were briefly
washed 2 times each with fresh PBS to remove any unbound f-heparin, dried with a
kimwipe and lyophilized.
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4.6 Heparin Quantitation
After lyophilization, the yarns were weighed and their diameters were measured
again to see if any significant changes in weight or morphology had occurred. Next, the
yarns were fluorescently imaged using an AMG EVOS FL cell imaging system to
visualize the f-heparin loading efficiency. To quantify the amount of f-heparin loaded, the
yarns were added to 200µL of PBS in individual wells of a black 96 well plate and their
fluorescence was read using a Biotek Synergy4 multi-detection plate reader. Fheparin/PBS standards were also generated and read on the same well plate as the fibers.
The standard curve was applied to the sample readings and the results were standardized
by dividing the amount of F-heparin loaded by each sample’s respective post heparinimmobilization and lyophilization weight. The negative control readings were averaged
and then subtracted from their corresponding samples to eliminate the noise caused by
the fiber itself.

4.7 Heparin Release Study
F-heparin immobilized yarns were placed in individual wells of a 24 well plate
and 1mL of pre-warmed 37˚C PBS was added to each well. The plate was protected from
light and incubated at 37˚C to mimic physiological conditions. At designated time points,
500µL of PBS was removed from each well and replaced with 500µL of fresh PBS. The
PBS that was removed from the release plate was pipetted into a black 96 well plate
(200µL each well, 2 wells per sample) and read by a microplate reader to measure its
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fluorescence (Excitation: 494nm Emission: 521nm). A standard curve of f-heparin/PBS
was used to quantify the readings.

4.8 Activated Partial Thromboplastin Time Study
To observe the activity of the immobilized heparin on the yarns, a timed clotting
test was performed. 400µL of 1x PBS (without Ca2+ and Mg2+) was added to each well of
a sterile 24 well plate. A pre-weighed yarn sample (~0.5mg) or 10µL of either a
heparin/PBS standard or PBS were added to the wells. 500µL of pre-warmed (37˚C)
bovine platelet rich plasma (PRP) was then added to each well and the plate was shaken
gently for 5 minutes at room temperature. Following shaking, the plate was incubated for
20 minutes at 37˚C to mimic physiological conditions. 0.1M calcium chloride (CaCl2)
was prepared in filtered deionized water and warmed to 37˚C in a water bath. 100µL of
the CaCl2 was added to each well to activate the coagulation cascade, and the time it took
for each well to form a clot was recorded. A clot was observed when the clear solution
started to become cloudy, eventually leading to a gel-like phase. The assay was run twice
with 3 of each sample tested per run. The average times were taken and compared against
control wells.
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Chapter 5
Results and Discussion
5.1 Synthesis and Characterization of PgP
PgP was synthesized using branched polyethylenimine (bPEI or PEI, MW 25kDa)
and poly-D,L-(lactide-co-glycolide) (PLGA, MW 50kDa (50:50 lactide:glycolide)) To
test the effect of the amount of hydrophobic polymer has on the composition ratio of
PLGA:PEO:PgP, heparin loading efficiency and mechanical strength, two different PgPs
were synthesized using two different mole ratios of PLGA to PEI (PLGA:bPEI=1.2 :1
and 10:1). Following synthesis and purification, the structure and grafting ratio of PLGA
to bPEI were confirmed by 1H-NMR (Bruker 300MHz) using DMSO-d6 as a solvent.
(δ=2.4~3.5 (m, PEI backbone -CH2), δ=1.4~1.6 (d, 3H, PLGA -CH3), δ=4.3 (q, 1H,
PLGA-CH), δ=3.9 (s, 2H, PLGA –CH2)). In case of PgP1, the ratio of the integrals of
the PEI backbone (δ=2.4~3.5) to the methylene of PLGA (δ=3.9) indicated that
approximately 1 PLGA (MW: 50 kDa) was grafted to each bPEI (figure 1A). In case of
PgP 3.7, 3.7 of PLGA was grafted to each bPEI (figure 1B).
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Figure 1. NMR spectrum of PgP1 (A) and PgP 3.7 (B)
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5.2 Electrospinning
As previously described, there are a number of factors that influence the
spinability, fiber morphology and mechanical properties of the resulting fibers.
5.2.1 Polymer selection
The polymers that were selected to be electrospun were chosen based on several
factors. PLGA is FDA approved for use in humans and is one of the polymers used in
common commercially available sutures [28]. It can also be dissolved in a wide range of
common solvents [29], which aids in its ability to be electrospun [12]. The choice of high
molecular weight PLGA was based on several reasons. First, since molecular weight is
correlated with solution viscosity, the increased viscosity allows for continuous fiber
formation as well as more uniform fiber diameter [12]. The high molecular weight is also
shown to decrease degradation rates [30], an important characteristic in absorbable
sutures.
Poly(ethylene oxide) (PEO), an amphiphilic polyether diol, is non-toxic and can
be eliminated via hepatic and renal pathways. It was selected due to its ability to facilitate
electrospinning of other polymers that are unable to be spun and improve the fiber’s
properties [31][32]. Although PEO is highly soluble in water, potentially negatively
impacting the mechanical strength of the overall yarn, it has been shown that nanofibers
fabricated with around 10wt% experienced no significant change in morphology and its
fibrous structure was retained after 7 days immersed in water [33]. PEO’s swelling
properties in water allow for the void created by the suture needle to be filled, which is
particularly useful in cardiovascular applications where minimal leakage at anastomosis
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sites is desired [8]. Moreover, based on preliminary experiments, PgP could not be
electrospun with PLGA alone; it wasn’t until the addition of 2w/v% was added to the
polymer solution. Furthermore, other preliminary studies of the effect of heparin
immobilization and lyophilization on the yarns mechanical properties showed similar
rates of reduced strength from pure PLGA yarns compared to PLGA/PEO and
PLGA/PEO/PgP yarns.
5.2.2 Polymer Concentration
The concentration of each polymer used was determined by both literature review
and experimentation. As described above, the low PEO concentration (2% w/v) allowed
for PgP to be electrospun in the blend while avoiding extreme mechanical and
morphological degradation in vivo [33]. PLGA has been electrospun in a number of
studies at various concentrations, frequently between 10-20% w/v [34][35][36][37].
Through preliminary testing and mechanical testing, it was determined that 13% PLGA
provided the most favorable fiber properties. PgP concentration was determined simply
by its maximum solubility in the polymer solution blend. By increasing the ratio of
PLGA:PEI in the PgP polymer, more PgP was able to be dissolved in the blend,
ultimately allowing for a higher concentration of PEI electrospun into the fibers.
5.2.3 Solvent selection
The choice of solvent for the polymer solution has a big influence on its
spinability, since most importantly it must be able to dissolve the polymer blend
completely while maintaining the integrity of the polymer itself. Since PgP has shown
poor solubility in many solvents commonly used for electrospinning, preliminary studies
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were carried out to determine a suitable solvent. Through trial and error, it was
determined dimethylacetamide (DMAc) was able to produce continuous, uniform fibers.
However, in order to dissolve all 3 polymers and maintain an appropriate viscosity for
electrospinning, the solution had to be heated to 60˚C and maintained throughout the
electrospinning process. This was achieved by wrapping the electrospinning syringe in a
heat sleeve.
5.2.4 Parameter Optimization
As stated in the background section on electrospinning, there are a multitude of
variables that affect the electrospun fiber spinnability and morphology [13]. The applied
voltage, gap distance, polymer flow rate, needle gauge, relative humidity, all must be
optimized and then remain consistent for repeatability. However, based on the polymer
solution being electrospun, they were adjusted slightly for best results the gap distance
was set between 20-25cm, needle gauge was 21, polymer flow rate was 0.25mL/hr,
applied voltage was +12kV -2kV, and relative humidity was between 40-60%. The
twisting of the fibers into yarns has also been shown to improve mechanical strength of
the yarn [38].

5.3 Electrospun Yarn Characterization
5.3.1 Physical Characterization
The scanning electron microscopy (SEM) images (figure 2) show the surface
morphology of the electrospun fibers produced with and without PgP. The relatively
smooth surface of the yarns and the uniform nanofiber diameter are both favorable
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properties for suture design and mechanical strength, respectively. It can also be observed
that the fibers are uniformly oriented, which has been shown to improved mechanical
strength of the yarn [13][39][40].

Figure 2. SEM images of electrospun yarns

5.3.2 Mechanical Characterization
The mechanical properties of the yarns are given below. The fiber diameter’s
were approximated to USP 6-0 size, slightly larger than sutures typically used for
microvascular anastomosis but still small enough for vascular applications elsewhere in
the body [41]. While the only standard requirement set forth by the United States
Pharmacopeia (USP) is a suture’s minimum knot-pull tensile strength [8], the elastic
modulus and elongation at break values provide insight into the overall mechanical
behavior of the yarns and are frequently provided in similar literature
[28][8][19][9][22][35].
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As seen in the stress-strain plots (figure 3), the yarns containing the PgP show a
much larger elongation at break value than the non-PgP yarns. Apart from this however,
there was only a significant difference in the elastic moduli between the PgP and non-PgP
fibers which is a good measure of the material’s stiffness. It must be noted, however, that
the mechanical strength displayed in the yarns are well below the standards for
comparable absorbable sutures of similar diameters. While the tensile strength of the
yarns in this study were around 15 MPa, sutures of similar size require strengths
approximately 20x higher as provided by the USP.
Comparable commercially available sutures like Ethicon’s Vicryl® suture, which
is an absorbable multifilament suture composed of PLGA, has a minimum ultimate
strength of 410 MPa and a minimum elastic modulus of 1.4 GPa [8]. Moreover, studies
were done on the mechanical strength of the yarns after heparin immobilization and
lyophilization as well as seven days after incubation in PBS at 37˚C which showed
significant decreases in mechanical strengths. These significant discrepancies between
the electrospun yarns and the commercial suture consisting of similar polymers show
how PLGA itself isn’t the problem but that the various other parameters all contribute to
the final product’s mechanical properties.
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Figure 3. Stress-strain plots of select PP (A) PPP 1 (B) and PPP 3.7 (C) yarns

Table 1. Mechanical Properties of corresponding electrospun yarns

Fiber Type
PPP 3.7
PPP 1
PP

Fiber Diameter
[μm]

Elastic Modulus
[MPa]

92.74±20.11

453.25±31.95

67.2±18.4

13.4±4.37

105.56±18.67
93.00±5.93

487.55±31.82
666.99±52.85

78.44±5.71
2.90±1.48

23.34±4.97
10.93±3.07
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Elongation at Tensile Strength
Break (%)
[MPa]

5.4 Heparin Loading and Release
Heparin was surface immobilized for several reasons. The possibility of the
heparin being denatured due to the solvent (DMAc) or the high voltage necessary for
electrospinning is avoided, while the high surface to volume ratio of the nanofibers is
able to be used to load high concentrations of heparin. More importantly, preliminary
studies testing the feasibility of incorporating heparin in the polymer blend prior to
electrospinning produced fibers with very poor mechanical properties. While it was
observed that mechanical properties decreased after heparin surface immobilization, they
were still far superior to the heparin blended fibers.
By surface immobilizing heparin post-electrospinning, the ionic bonding between
the negatively charged sulfate groups on heparin and the positively charged amine groups
on the PEI allow for these electrostatic interactions to bind more heparin per mg fiber
(figure 4). As expected, the increase in the total amount of PEI present in each yarn
resulted in an increased amount of immobilized heparin. The presence of immobilized
heparin on the PP fiber is due to hydrophobic interactions, which are weaker than
electrostatic but still exhibit some level of attraction. The heparin loading was also shown
visually via fluorescent microscopy (figure 5). While the discrepancies between images is
hard to observe, it is import to note that the difference in heparin loading between each
yarn is on the microgram level.
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Table 2. Yarn composition, PEI composition and heparin loading amount for each yarn type

Fiber
Type

Fiber Composition
(Weight Ratio, w/v %)
PPP 3.7 PLGA:PEO:P3.7gP (13.0:2.0:1.5)
PPP 1 PLGA:PEO:PgP (13.0:2.0:0.39)
PP PLGA:PEO (13.0:2.0)

PEI Amount
[w/v %]

Heparin Loading
[µg/mg fiber]

0.179
0.132
0

3.21±0.12
1.63±0.21
1.03±0.06

Figure 4. Heparin loading amount for each fiber. * p<0.05 compared to PP fiber
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Figure 5. Fluorescent microscopy (10x magnification) of heparin-immobilized fibers

The release profile of heparin from the yarns over a 20 day period can be seen
below (figure 6A). The electrostatic effect is observed again through the slightly slower
rate of release over the first few days. While all 3 yarns displayed burst release, there
were significant differences between each fiber, especially over the first 8 hours (figure
6B). The PP yarn had released over 70% of the heparin that was immobilized, while the
PPP 1 yarn only released around 50% and the PPP 3.7 yarn slightly over 25%. This initial
burst release is a favorable characteristic since bolus injections of heparin are commonly
applied to the wound area during surgery anyway. It has been shown that immediate
heparin treatment is more effective than delayed administration for preventing the
myoproliferative response [42]. Vascular smooth muscle cell (VSMC) proliferation is
highest in the first week of injury, and heparin release was sustained well past this point
[14].
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Figure 6. Release profiles of PP, PPP 1 & PPP 3.7 yarns over 20 days (A) and zoomed in profile over first
8 hours (B)
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5.5 Immobilized Heparin Therapeutic Activity
The activated partial thromboplastin time (APTT) is a medical test that is used to
monitor the effects of heparin on blood [43]. This test was used to test the therapeutic
effect of the immobilized heparin. Heparin inhibits factors X and thrombin, while
activating anti-thrombin. The calcium chloride is added to activate the coagulation
cascade. A 0.1 µg heparin sample was used as standard, and the time for each sample to
form a gel-like ‘clot’ was recorded. The results reflected the expected outcome, with the
yarns with higher concentrations of immobilized heparin yield higher clotting times. By
comparing the clotting time of 0.1 µg to the clotting times of the yarn samples, it can be
broken down to follow the release rates of heparin on a per milligram basis.

Figure 7. Clotting times of each type of heparin-immobilized yarn *p<0.05 compared to 0µg heparin
solution
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Chapter 6
Conclusion and Future Studies
6.1 Conclusion
The goal of this project was to explore the feasibility of a heparin immobilized
electrospun yarn as an absorbable suture, specifically for vascular applications. Since the
electrospinning process involved a novel polymer (PgP) that was difficult to electrospin,
optimizing the electrospinning conditions and polymer blends enabled for uniform fiber
formation. The customized collector/twisting device successfully twisted the aligned fiber
mass into smooth yarns with little to no surface defects confirmed with SEM imaging.
The project was developed around the application of the PgP polymer to improve
heparin loading efficiency and release kinetics of yarns in comparision to non-PgP yarns
by taking advantage of the electrostatic attraction between the heparin and PEI in PgP.
This goal was accomplished through heparin loading and release studies, showing
increased heparin loading amounts in yarns with increased PEI presence. The release
profiles also demonstrated a slower, more sustained release of heparin from the yarns
with the higher PEI concentrations. To ensure the immobilized heparin was still
therapeutically active, an APPT test was performed to measure the clotting times for each
sample. Further success was shown with increased clotting times for fibers loaded with
more heparin.
The mechanical testing of the fibers was not as successful as the studies prior. All
of the fibers tested fell well below the minimum strength requirements for synthetic
absorbable sutures of the same size. However, there are several post spinning treatments
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and coatings that can be applied to greatly improve the mechanical properties. While
some alternative polymers were tested with PgP already in preliminary studies, there still
remains other options to optimize the yarn strength.

6.2 Limitations and Future Studies
While the loading and release data is promising, the mechanical properties need to
significantly improve for the yarn to feasible as a surgical suture. In order to achieve this,
either a pivot in the project direction needs to be taken where the PgP-heparin loaded
fibers are used for an alternative application, or a major processing parameter needs to be
changed such as the yarn fabrication method or the polymer solution combination.
Incorporating multiple drugs into the yarns for a combinatorial approach is another option
to consider for the current state of the project.
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